Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Rock Rolls

This article was originally published in Start Up

Executive Summary

Founded by a team of former Millennium Pharmaceutical executives including former CEO Mark Levin, Third Rock Ventures intends to return to the venture capital model of old. The Boston-based firm intends to start companies that can leverage a novel technology capable of creating multiple drugs for multiple diseases.

You may also be interested in...



Few Exits, But Lots Of Cash: Third Rock Closes $516M Third Fund

The early-stage biotech venture firm drew its largest fund yet, topping $1 billion raised since inception, despite notching only two exits from its first two funds.

The A-List: 2008's Trend Shaping Series A Financings

Despite a miserable economy, new company formation continues apace. In biotech, recapitalizations and structured deals featured prominently; in diagnostics, interest remains strong even if rounds in 2008 were down from last year's highs; in devices, small and regional VCs have filled the void left by brand-name investors.

The A-List: 2008's Trend Shaping Series A Financings

Despite a miserable economy, new company formation continues apace. In biotech, recapitalizations and structured deals featured prominently; in diagnostics, interest remains strong even if rounds in 2008 were down from last year's highs; in devices, small and regional VCs have filled the void left by brand-name investors.

Related Content

Related Companies

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel